Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck R&D Renaissance To Continue With Three NDA Filings In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.

You may also be interested in...



Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

Firm reports first-quarter revenues of over $1 billion.

Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

Firm reports first-quarter revenues of over $1 billion.

Merck Aims To Duplicate Januvia Launch Success In 2007

Launches for Janumet, Arcoxia and Emend IV are keys to continuing the momentum of firm’s turnaround plan, CEO Clark says.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel